UY33125A - Diaza-espiro-[5,5]-undecanos - Google Patents

Diaza-espiro-[5,5]-undecanos

Info

Publication number
UY33125A
UY33125A UY33125A UY33125A UY33125A UY 33125 A UY33125 A UY 33125A UY 33125 A UY33125 A UY 33125A UY 33125 A UY33125 A UY 33125A UY 33125 A UY33125 A UY 33125A
Authority
UY
Uruguay
Prior art keywords
undecanes
diaza
spiro
Prior art date
Application number
UY33125A
Other languages
English (en)
Inventor
Sangamesh Badiger
Dirk Behnke
Claudia Betschart
Vinod Chaudhari
Simona Cotesta
Jurgen Hans-Hermann Hinrichs
Silvio Ofner
Chetan Pandit
Jurgen Wagner
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IN2663DE2009 priority Critical
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY33125A publication Critical patent/UY33125A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
UY33125A 2009-12-21 2010-12-21 Diaza-espiro-[5,5]-undecanos UY33125A (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN2663DE2009 2009-12-21

Publications (1)

Publication Number Publication Date
UY33125A true UY33125A (es) 2011-07-29

Family

ID=43640117

Family Applications (1)

Application Number Title Priority Date Filing Date
UY33125A UY33125A (es) 2009-12-21 2010-12-21 Diaza-espiro-[5,5]-undecanos

Country Status (9)

Country Link
US (1) US8530648B2 (es)
EP (1) EP2516439B1 (es)
JP (1) JP2013515033A (es)
CN (1) CN102762567A (es)
AR (1) AR079553A1 (es)
ES (1) ES2459496T3 (es)
TW (1) TW201132642A (es)
UY (1) UY33125A (es)
WO (1) WO2011076747A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120101110A1 (en) * 2010-10-26 2012-04-26 Sangamesh Badiger Diaza-spiro[5.5]undecanes
US20120165331A1 (en) * 2010-12-22 2012-06-28 Sangamesh Badiger Di/tri-aza-spiro-C9-C11alkanes
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
MX2014009281A (es) 2012-02-07 2015-01-12 Eolas Therapeutics Inc PROLINES / PIPERIDINS REPLACED AS ANTAGONISTS OF THE RECEIVER OF OREXINA.
ITMI20120424A1 (it) 2012-03-19 2013-09-20 Rottapharm Spa Composti chimici
CA2945687A1 (en) * 2014-01-27 2015-07-30 Allergan, Inc. Antagonists acting at multiple prostaglandin receptors for the treatment of inflammation
JP2017100951A (ja) * 2014-04-04 2017-06-08 大正製薬株式会社 オキサゾリジノン及びオキサジナノン誘導体
WO2016025669A1 (en) 2014-08-13 2016-02-18 Eolas Therapeutics, Inc. Difluoropyrrolidines as orexin receptor modulators
AU2016295693B2 (en) 2015-07-17 2020-05-21 Sunshine Lake Pharma Co., Ltd. Substituted quinazoline compounds and preparation and uses thereof
MX2018009656A (es) 2016-02-12 2019-02-20 Astrazeneca Ab Piperidinas halo-sustituidas como moduladores de los receptores de orexinas.
CN106831774B (zh) * 2017-02-07 2019-02-01 上海合全药业股份有限公司 一种(6s,7s)-9-叔丁氧羰基-7-(三氟甲基)-2,9-二氮杂螺[5.5]十一烷的合成方法
CA3089561A1 (en) * 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2020158415A1 (ja) * 2019-01-28 2020-08-06 サントリーホールディングス株式会社 オレキシン受容体拮抗阻害用組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
JP4496722B2 (ja) * 2002-06-28 2010-07-07 萬有製薬株式会社 新規ベンズイミダゾール誘導体
WO2007025069A2 (en) * 2005-08-26 2007-03-01 Merck & Co., Inc. Diazaspirodecane orexin receptor antagonists
DK1961744T3 (da) * 2005-11-18 2013-07-15 Ono Pharmaceutical Co Forbindelse indeholdende basiske grupper samt anvendelse deraf

Also Published As

Publication number Publication date
AR079553A1 (es) 2012-02-01
EP2516439A1 (en) 2012-10-31
TW201132642A (en) 2011-10-01
US20120264748A1 (en) 2012-10-18
US8530648B2 (en) 2013-09-10
ES2459496T3 (es) 2014-05-09
CN102762567A (zh) 2012-10-31
EP2516439B1 (en) 2014-01-22
JP2013515033A (ja) 2013-05-02
WO2011076747A1 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
ES2537658T3 (es) Spiro amino compounds suitable for the treatment of (among others) sleep disorders and drug addiction
AR077277A1 (es) Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
AT557427T (de) MODULAR BATTERY PACK
UY33125A (es) Diaza-espiro-[5,5]-undecanos
AR078553A1 (es) COMPOSITION OF LOW ETER CONTENT AND ADMINISTRATION APPLIANCE
AR070418A1 (es) Metodo y aparato para determinar la dilatacion de un material mediante un dispositivo sensor de error de foco
AR075383A1 (es) Derivados de triazolo[4,3-b]piridazina
AR075596A1 (es) PROCESS TO PREPARE 1,2-PROPANODIOL FROM HYDROGENATION OF GLICEROL
AR079654A1 (es) ANTI-BANK COMBINATIONS OF ARTEMISININE-BASED PHARMACOS AND OTHER CHEMOTHERAPEUTIC AGENTS. USE. PHARMACEUTICAL COMPOSITION PREPARATION PROCEDURE TREATMENT METHOD
AR076617A1 (es) COMPOUNDS OF AMINOPIRAZOL TRIAZOLOTIADIAZOL INHIBITORS OF PROTEIN QUINASE C-MET.
AR075781A1 (es) Derivados de oxadiazol piridina como agonistas del receptor s1p1/edg1 y un metodo para su preparacion.
AR076805A1 (es) Plataforma de servicios
AR070776A1 (es) Dispositivo para diagnosticar el estado fisiologico y/o seleccionar los mejores espermatozoides de una muestra de semen en base a quimiotaxis y procedimiento de uso del mismo
AR078359A1 (es) A PROCESS TO USE HARD TO HIGH ALKALINE SALMUERA FOR IMPROVED OIL RECOVERY APPLICATIONS
AR073581A4 (es) Equipo de transmision de movimiento con tres engranajes polimericos
AR073005A1 (es) Un dispensador de bolsas desprendibles
AR071077A4 (es) Membrana aislante y antideslizante para cubiertas de techo
AR070784A1 (es) Balanza para fertilizadoras
AR070742A1 (es) Dispositivo para proteger las cubiertas de las ruedas delanteras de una sembradora
AR070739A2 (es) Compuesto analogo de glp -1
AR070730A1 (es) Equipo que obtiene extractos de yerba mate a semejanza con la modalidad de cebadura para estudios sensoriales, fisicos y quimicos
AR070499A4 (es) Ruedas de vehiculos tradicionales con camaras de aire inflables
AR070483A1 (es) Motor rotativo con camaras de expansion perifericas de seccion variable
AR070446A1 (es) Polvo de cabon aditivado con carbohidratos solubles en agua para el uso en la composicion de arena verde para el moldeo de vaciados
AR070708A1 (es) Metodo para proporcionar material celular derivado de sangre periferica facilmente disponible y composicion del mismo

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181127